BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

Search

Main Street Capital Corp

Chiusa

SettoreFinanza

55.01 0.57

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

54.02

Massimo

55.54

Metriche Chiave

By Trading Economics

Entrata

-92M

32M

Vendite

19M

203M

P/E

Media del settore

9.973

54.048

EPS

1.03

Rendimento da dividendi

5.5

Margine di Profitto

15.749

Dipendenti

110

EBITDA

3.3M

137M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+24.21% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

5.50%

4.84%

Utili prossimi

11 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-63M

5B

Apertura precedente

54.44

Chiusura precedente

55.01

Notizie sul Sentiment di mercato

By Acuity

34%

66%

73 / 441 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Main Street Capital Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 mar 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Discorsi di Mercato

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Discorsi di Mercato

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Principali Notizie su Eventi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato
Utili
Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Main Street Capital Corp Previsione

Obiettivo di Prezzo

By TipRanks

24.21% in crescita

Previsioni per 12 mesi

Media 68.33 USD  24.21%

Alto 74 USD

Basso 65 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Main Street Capital Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

52.6034 / 54.64Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

73 / 441 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Main Street Capital Corp

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations, and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies ranging between $5 million and $125 million in equity investment with annual revenues between $10 million and $150 million and EBITDA in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $150 million per transaction in debt investment value but holds the ability to lead debt financings up to $250 million and invests between $10 million and $150 million in credit solutions with EBITDA in the range of $5 million and $75 million for credit solutions. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minori
help-icon Live chat